Cochrane Abstracts
Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Pegylated Liposomal Doxorubicin for First‐line Treatment of Epithelial Ovarian Cancer." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434128/all/Pegylated_liposomal_doxorubicin_for_first‐line_treatment_of_epithelial_ovarian_cancer.
Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434128/all/Pegylated_liposomal_doxorubicin_for_first‐line_treatment_of_epithelial_ovarian_cancer. Accessed January 24, 2025.
Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434128/all/Pegylated_liposomal_doxorubicin_for_first‐line_treatment_of_epithelial_ovarian_cancer
Pegylated Liposomal Doxorubicin for First‐line Treatment of Epithelial Ovarian Cancer [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 January 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434128/all/Pegylated_liposomal_doxorubicin_for_first‐line_treatment_of_epithelial_ovarian_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer
ID - 434128
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434128/all/Pegylated_liposomal_doxorubicin_for_first‐line_treatment_of_epithelial_ovarian_cancer
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
